Absorption Efterfølgende subkutan administration af 240 mg degarelix ved en koncentration på 40 mg/ ml til patienter med prostatakræft i det pivotale forsøg CS21, var AUC0- 28 days 635 (602- 668) dag* ng/ ml, Cmax var 66, 0 (61, 0- 71, 0) ng/ ml og forekom ved tmax ved 40 (37- 42) timer.
Absorption Following subcutaneous administration of 240 mg degarelix at a concentration of 40 mg/ ml to prostate cancer patients in the pivotal study CS21, AUC0-28 days was 635 (602-668) day*ng/ ml, Cmax was 66.0 (61.0-71.0) ng/ ml and occurred at tmax at 40 (37-42) hours.